

# CITATION REPORT

List of articles citing

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

DOI: 10.1093/ajh/5.2.95

American Journal of Hypertension, 1992, 5, 95-110.

**Source:** <https://exaly.com/paper-pdf/22929336/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
871	Blood pressure control and regression of LV hypertrophy in dialysis patients. <b>1994</b> , 106, 110-3		4
870	The stroke preventive effect in elderly hypertensives cannot fully be explained by the reduction in office blood pressure--insights from the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). <b>1992</b> , 1, 168-72		21
869	Effect of diuretic therapy on hypertensive left ventricular hypertrophy. <b>1992</b> , 13 Suppl G, 53-60		22
868	Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. <b>1992</b> , 107, 970-5		100
867	Blood pressure reduction and recovery of stunned myocardium in the hypertrophied hypertensive heart. <b>1992</b> , 20, 1003-4		1
866	An editorial comment on Dr. Opie's editorial. <b>1992</b> , 6, 563-564		
865	Angiotensin-converting enzyme inhibitors as cardioprotective agents. <b>1992</b> , 70, 101-171		4
864	The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. <b>1993</b> , 234, 271-9		24
863	Effects of sustained-release isradipine on left ventricular anatomy and function in systemic hypertension. <b>1993</b> , 72, 1301-4		8
862	Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. <b>1993</b> , 72, 794-8		67
861	Left ventricular hypertrophy: should it be reduced?. <b>1993</b> , 16, 1115-20		
860	The cardiologist's approach to evaluation and management of the patient with essential hypertension. <b>1993</b> , 126, 648-66		4
859	Antihypertensive therapy to maximally reduce coronary risk. <b>1993</b> , 125, 1487-93		4
858	Cardiac effects of trandolapril in hypertension. <b>1993</b> , 125, 1536-41		11
857	The cardiac renin-angiotensin system in heart failure. <b>1993</b> , 126, 756-60		30
856	Pharmacokinetic drug interactions with ACE inhibitors. <b>1993</b> , 25, 20-58		51
855	Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy. <b>1993</b> , 46 Suppl 2, 88-94		3

854	Individualised selection of antihypertensive therapy. <b>1993</b> , 46 Suppl 2, 142-8		6
853	Cardioreparation and the concept of modulating cardiovascular structure and function. <b>1993</b> , 2, 6-21		29
852	The Nordic Diltiazem Study (NORDIL). A prospective intervention trial of calcium antagonist therapy in hypertension. <b>1993</b> , 2, 312-21		44
851	Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death. <i>American Journal of Hypertension</i> , <b>1993</b> , 6, 335-6	2.3	14
850	Treatment of Mild Hypertension Study. <b>1993</b> , 270, 713		544
849	Treatment of Mild Hypertension. <b>1993</b> , 270, 757		7
848	STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Swedish Trial in Old Patients with Hypertension. <b>1993</b> , 2, 136-41		79
847	The promises and perils of treating the elderly hypertensive. <b>1993</b> , 305, 183-97		14
846	Left ventricular function and regression of left ventricular hypertrophy in essential hypertension. <i>American Journal of Hypertension</i> , <b>1993</b> , 6, 14S-19S	2.3	21
845	Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension. <b>1993</b> , 83 Suppl 1, 57-63		3
844	The place of diuretics in the treatment of hypertension in 1993: can we do better?. <b>1993</b> , 15, 1239-55		7
843	Beneficial effect of isradipine on the development of left ventricular hypertrophy in mild hypertension. <i>American Journal of Hypertension</i> , <b>1993</b> , 6, 95S-97S	2.3	7
842	Ischaemia and left ventricular hypertrophy. <b>1993</b> , 14 Suppl F, 2-6		160
841	A multifactorial approach to coronary disease risk assessment. <b>1993</b> , 15, 1077-86		6
840	Left ventricular end-diastolic dimensions measured at the P wave and Q wave during a randomized, double-blind one-year follow-up study comparing the effect of atenolol vs. hydrochlorothiazide + amiloride on blood pressure in men with mild to moderate hypertension. <b>1993</b> , 53, 155-62		
839	From Syndrome X to the Thrifty Phenotype: A Reappraisal of the Insulin Resistance Theory of Atherogenesis. <b>1993</b> , vnr-4, 19-47		2
838	Hypertension. <b>1993</b> , 159, 604-608		2
837	Hypertension and the heart. <b>1994</b> , 50, 299-321		14

836	Differential effects of antihypertensive drugs on hypertension: associated risk factors. <b>1994</b> , 85 Suppl 1, 78-83	
835	Hypertension and left ventricular hypertrophy: is drug therapy beneficial?. <b>1994</b> , 14, 60-88	5
834	Bibliography. <b>1994</b> , 160, S16	
833	Angiotensin-Converting Enzyme Inhibitors in Hypertension. <b>1994</b> , 154, 513	51
832	Some thoughts on pathogenesis, therapy and prevention of hypertension. <b>1994</b> , 3, 7-17	20
831	Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. <b>1994</b> , 23, 258-68	150
830	Can the Cost of Care Be Contained and Quality of Care Maintained in the Management of Hypertension?. <b>1994</b> , 154, 1665	
829	Forearm blood flow reserve and cardiac and renal indexes of pressure load in normotensive and hypertensive individuals. <b>1994</b> , 24, 24-9	12
828	Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. <b>1994</b> , 90, 1786-93	501
827	Role of ACE inhibitors in hypertension with left ventricular hypertrophy. <b>1994</b> , 72, S24-32	6
826	Role of ACE inhibitors in uncomplicated essential hypertension. <b>1994</b> , 72, S15-23	4
825	Electron microscopic study on regression of cardiac hypertrophy in spontaneously hypertensive rats. <b>1994</b> , 27, 239-242	1
824	Evidence for cardiovascular remodeling in a patient with Bartter's syndrome. <b>1994</b> , 72, 874-7	5
823	Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. <b>1994</b> , 8 Suppl 3, 549-56	32
822	Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death. <b>1994</b> , 8 Suppl 3, 557-63	14
821	Effects of bisoprolol on left ventricular hypertrophy in essential hypertension. <b>1994</b> , 8, 837-43	5
820	Salt intake, blood pressure, and cardiovascular structure. <b>1994</b> , 8, 425-32	14
819	Effects of enalapril and hydrochlorothiazide on the salt-induced cardiac and renal hypertrophy in normotensive rats. <b>1994</b> , 350, 416-25	4

818	Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients. <b>1994</b> , 74, 36A-42A	12
817	Effectiveness of enalapril in combination with low-dose hydrochlorothiazide versus enalapril alone for mild to moderate systemic hypertension in black patients. <b>1994</b> , 73, 1092-7	29
816	Disparate structural effects on left and right ventricles by angiotensin-converting enzyme inhibitors and calcium antagonists in essential hypertension. <b>1994</b> , 73, 483-7	24
815	Antihypertensive drugs: issues beyond blood pressure control. <b>1994</b> , 36, 397-415	8
814	Effects of antihypertensive drugs on cardiac hypertrophy. <b>1994</b> , 29, 197-215	5
813	Cardiac Renin-Angiotensin System in Cardiac Hypertrophy and Failure. <b>1994</b> , 91-99	2
812	Normalization of cardiac structure and function after regression of cardiac hypertrophy. <b>1994</b> , 128, 333-43	23
811	Microalbuminuria and endothelial dysfunction in essential hypertension. <b>1994</b> , 344, 14-8	320
810	[Left ventricular hypertrophy of hypertensive origin: classical concepts and recent data]. <b>1994</b> , 15, 30-6	2
809	The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials. <b>1994</b> , 5, 171-83	44
808	Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension. <b>1994</b> , 6, 155-82	6
807	Echocardiography should be performed in all elderly patients with congestive heart failure. <b>1994</b> , 42, 1300-2	38
806	Individualization of therapy for hypertension in the 1990's: the role of calcium antagonists. <b>1994</b> , 16, 853-64	5
805	Assessment of echocardiographic left ventricular mass before and after acute volume depletion. <i>American Journal of Hypertension</i> , <b>1994</b> , 7, 425-8	2.3 12
804	Left ventricular diastolic dysfunction. <b>1994</b> ,	
803	Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. <b>1994</b> , 50, 272-98	388
802	Angiotensin I converting enzyme gene: regulation, polymorphism and implications in cardiovascular diseases. <b>1994</b> , 15 Suppl D, 24-9	30
801	Prescribing Medication Versus Promoting Behavioural Change: A Trial of the Use of Lifestyle Management to Replace Drug Treatment of Hypertension in General Practice. <b>1994</b> , 11, 177-185	3

800	Hypertension: are beta-blockers and diuretics appropriate first-line therapies?. <b>1994</b> , 28, 617-25	6
799	Left ventricular hypertrophy in hypertension--general and local trends in diagnosis and therapy. <b>1994</b> , 39, 35-7	1
798	Directions in antihypertensive treatment--our future from the past. <b>1995</b> , 16 Suppl C, 74-83	8
797	Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. <b>1995</b> , 35, 1052-9	7
796	Hypertension therapy and risk of coronary heart disease: how do antihypertensives affect metabolic factors?. <b>1995</b> , 86, 89-93	5
795	Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. <b>1995</b> , 16, 1120-5	14
794	The effects of antihypertensive therapy on carotid vascular structure in man. <b>1995</b> , 30, 147-152	27
793	Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. <b>1995</b> , 30, 570-584	55
792	Noninvasive assessment of left ventricular mass, chamber volume, and contractile function. <b>1995</b> , 20, 364-440	27
791	Implications for cost-effectiveness. Combination therapy for systemic hypertension. <b>1995</b> , 76, 595-7	27
790	Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. <b>1995</b> , 76, 50E-54E	22
789	Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. <b>1995</b> , 147, 89-97	54
788	Angiotensin converting enzyme (ACE) inhibitors and kinin metabolism: evidence that ACE inhibitors may inhibit a kininase other than ACE. <b>1995</b> , 22, 903-11	29
787	Tissue angiotensin generation and regulation of vascular tone. <b>1995</b> , 65, 193-213	20
786	Ventricular tachyarrhythmias, myocardial ischemia, and sudden cardiac death in patients with hypertensive heart disease. <b>1995</b> , 18, 377-83	16
785	Effects of ACE inhibition on cardiovascular risk factors, insulin resistance, and microalbuminuria. <b>1995</b> , 18, I-3-I-11	
784	Effects of ACE inhibition on the hypertrophied heart-implications for reversal and prognosis: An updated review. <b>1995</b> , 18, I-12-I-22	
783	Physiologic effects of long-term hypertension control. <b>1995</b> , 18, III 17-22	12

782	Antihypertensive therapy targeted to the needs of the patient: focus on the renin-angiotensin system; older and newer agents. <b>1995</b> , 18, III 23-8	
781	Beyond ACE inhibition: new developments in drug therapy for hypertension. <b>1995</b> , 162, 659-61	2
780	Converting enzyme inhibition and left ventricular hypertrophy. <b>1995</b> , 16, 1748-9	
779	Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment. <b>1995</b> , 16, 1981-7	8
778	Hypertension and Left-Ventricular Hypertrophy. <b>1995</b> , 13, 549-557	16
777	Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. <b>1995</b> , 17, 441-68	14
776	Blood pressure variability and its implications for antihypertensive therapy. <b>1995</b> , 4, 5-11	52
775	The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies. <b>1995</b> , 274, 620	491
774	Cellular mechanisms of cardiac hypertrophy. <b>1995</b> , 73, 496-9	34
773	Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril. <b>1995</b> , 4, 241-8	37
772	Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. <b>1995</b> , 333, 1462-7	234
771	Who needs nine ACE inhibitors?. <b>1995</b> , 33, 1-3	7
770	Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass. <i>American Journal of Hypertension</i> , <b>1995</b> , 8, 712-8	2.3 8
769	Organ protection and optimal blood pressure control. <i>American Journal of Hypertension</i> , <b>1995</b> , 8, 59S-62S.3	4
768	Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. <b>1995</b> , 17, 1005-30	15
767	Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. <b>1995</b> , 130, 1089-93	59
766	Left ventricular mass estimation by echocardiography: is it clinically useful?. <b>1995</b> , 12, 185-93	3
765	II agents: a new approach to the treatment of hypertension. <b>1995</b> , 763, 642-58	10

764	Association of carotid atherosclerosis and left ventricular hypertrophy. <b>1995</b> , 25, 83-90	206
763	Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. <b>1995</b> , 25, 424-30	163
762	Left ventricular hypertrophy. Prevalence in older patients and management. <b>1995</b> , 6, 301-11	3
761	ACE inhibitors. Differential use in elderly patients with hypertension. <b>1995</b> , 7, 355-71	20
760	Goals of antihypertensive therapy. <b>1995</b> , 49, 161-75	26
759	Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. <b>1995</b> , 49, 440-66	39
758	Choosing the right ACE inhibitor. A guide to selection. <b>1995</b> , 49, 516-35	51
757	Risk and management of hypertension-related left ventricular hypertrophy. <b>1995</b> , 50, 959-70	3
756	Selective versus nonselective beta adrenoceptor antagonists in hypertension. <b>1995</b> , 8, 513-23	3
755	Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. <b>1996</b> , 27, 1214-8	264
754	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. <b>1996</b> , 27, 978-90	80
753	Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension. <b>1996</b> , 132, 1004-9	20
752	Implications of the links between hypertension and myocardial infarction for choice of drug therapy in patients with hypertension. <b>1996</b> , 132, 222-228	6
751	Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. <i>American Journal of Hypertension</i> , <b>1996</b> , 9, 216-22	2.3 20
750	Blood Pressure as a Cardiovascular Risk Factor. <b>1996</b> , 275, 1571	635
749	Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. <b>1996</b> , 27, 347-54	548
748	Effect of echocardiography on clinical impact and patient outcome in hypertension. <b>1996</b> , 9, 585-90	2
747	Investigation of the relationship between regression of hypertensive cardiac hypertrophy and improvement of cardiac sympathetic nervous dysfunction using iodine-123 metaiodobenzylguanidine myocardial imaging. <b>1996</b> , 23, 756-61	16



746	Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. <b>1996</b> , 8, 38-46	3
745	Current drug treatment and treatment patterns with antihypertensive drugs. <b>1996</b> , 52, 1-16	21
744	Effects of Angiotensin-Converting Enzyme Inhibitors on the Heart and Vessels in Clinical and Experimental Hypertension. <b>1996</b> , 12, 226-243	6
743	Cardiovascular structural alterations in hypertension: effect of treatment. <b>1996</b> , 18, 513-22	3
742	Hypertension and Coronary Artery Disease in the Elderly. <b>1996</b> , 12, 41-56	5
741	The Effects of Amlodipine on Left Ventricular Mass and Diastolic Function in Concentric and Eccentric Left Ventricular Hypertrophy. <b>1996</b> , 1, 95-100	6
740	Antihypertensive treatment with diuretics: antediluvian or up to date?. <b>1996</b> ,	
739	Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. <b>1996</b> , 98, 2218-27	180
738	Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. <b>1996</b> , 44, 524-9	38
737	Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension. <b>1996</b> , 36, 98-111	28
736	Effects of angiotensin-converting enzyme inhibition on left ventricular geometric patterns in patients with essential hypertension. <b>1996</b> , 36, 1141-8	6
735	Options in antihypertensive drug therapy. Help in choosing from among the many agents. <b>1996</b> , 100, 89-94	
734	The DIAB-HYCAR Study. <b>1996</b> , 39, 1662-7	23
733	Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. <b>1996</b> , 77, 17b-19b	19
732	Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). <b>1996</b> , 78, 61-5	121
731	Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. <b>1996</b> , 38, 273-90	43
730	Effect of ACE inhibitors on endothelial dysfunction: unanswered questions and implications for further investigation and therapy. <b>1996</b> , 10, 469-73	9
729	Multivariate Analysis of Left Ventricular Mass Determinants in Adults: Different Patterns in Men and Women. <b>1996</b> , 13, 35-44	

728	Erythropoietin in chronic renal failure. <b>1996</b> , 50, 1373-91	58
727	Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. <b>1996</b> , 23 Suppl 3, S125-31	33
726	Hypertension, hypertrophy, heart failure. <b>1996</b> , 76, 92-7	9
725	Investigative Concerns in Demonstrating Reduced Risk From Reversing Left Ventricular Hypertrophy. <b>1996</b> , 1, 17-22	
724	Influence of measurement inaccuracies on determination of left ventricular mass by M mode echocardiography. <b>1996</b> , 75, 312-3	7
723	Cardiovascular disease and genetics of the renin-angiotensin system. <b>1996</b> , 76, 13-7	8
722	Congestive Heart Failure With Normal Left Ventricular Systolic Function. <b>1996</b> , 156, 146	76
721	Newer Approaches to Antihypertensive Therapy. <b>1996</b> , 156, 1969	65
720	The efficacy of felodipine ER on regression of left ventricular hypertrophy in patients with primary hypertension. <b>1996</b> , 5, 285-91	8
719	Hypertensive left ventricular hypertrophy: pathophysiology, assessment and treatment. <b>1996</b> , 5, 5-15	16
718	The Swedish Trial in old patients with hypertension-2 (STOP-hypertension-2): a progress report. <b>1996</b> , 5, 300-4	30
717	Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters. <b>1996</b> , 5, 154-63	3
716	Regression of Left Ventricular Hypertrophy. <b>1996</b> , 275, 1517	10
715	Antihypertensive treatment with diuretics: antediluvian or up to date?. <b>1996</b> , 11, 587-92	3
714	The effect of afterload and angiotensin II on proto-oncogene mRNA levels in the isolated working rat heart. <b>1996</b> , 31, 907-916	2
713	Acetylcholine induces contraction in vertebral arteries from treated hypertensive patients. <b>1996</b> , 18, 87-99	5
712	Cellular protective action of angiotensin converting enzyme inhibitors. <b>1997</b> , 105 Suppl 2, 61-3	
711	Efficacy of combination therapy with trandolapril and verapamil sr in primary hypertension: a 4 x 4 trial design. The Trandolapril Study Group. <b>1997</b> , 19, 373-87	10

710	Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. <b>1997</b> , 29, 286-90	96
709	The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status. <b>1997</b> , 6, 365-7	18
708	Factors influencing LVM in hypertensive type-1 diabetic patients. <b>1997</b> , 6, 197-202	5
707	Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event. <b>1997</b> , 15, 793-8	33
706	Mechanisms whereby calcium channel antagonists may protect patients with coronary artery disease. <b>1997</b> , 18 Suppl A, A92-104	17
705	Nocturnal blood pressure and relation to vasoactive hormones and renal function in hypertension and chronic renal failure. <b>1997</b> , 6, 332-42	32
704	Long-term inhibition of the renin-angiotensin system in genetic hypertension: analysis of the impact on blood pressure and cardiovascular structural changes. <b>1997</b> , 15, 339-48	45
703	Circulating angiotensin converting enzyme levels are increased in concentric, but not eccentric, left ventricular hypertrophy in elderly men. <b>1997</b> , 15, 885-90	8
702	Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. <b>1997</b> , 15, 1493-502	52
701	Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition. <b>1997</b> , 15, S3-7	15
700	Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension. <b>1997</b> , 15, S31-6	34
699	Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension. <b>1997</b> , 15, 309-17	10
698	Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. <b>1997</b> , 15, 719-26	49
697	Chapter 28 Mode of action of angiotensin converting enzyme inhibitors. <b>1997</b> , 8, 547-560	1
696	Amlodipine. <b>1997</b> , 13, 1-11	7
695	Hypertension and coronary artery disease. <b>1997</b> , 81, 1147-63	2
694	Antihypertensive therapy. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium antagonists. <b>1997</b> , 81, 1319-33	10
693	Disfunci3n diast3lica, hipertrofia ventricular izquierda y microalbuminuria en la hipertensi3n arterial esencial ligera-moderada. <b>1997</b> , 50, 233-238	4

692	Fosinopril. Clinical pharmacokinetics and clinical potential. <b>1997</b> , 32, 460-80		26
691	Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. <b>1997</b> , 130, 53-9		41
690	Inhibitor index: a novel method for measuring pharmacological inhibition of angiotensin-converting enzyme. <b>1997</b> , 6, 103-8		1
689	Diastolic dysfunction in heart failure. <b>1997</b> , 3, 225-42		50
688	Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. <b>1997</b> , 3, 133-48		38
687	Management of Primary Hypertension. <b>1997</b> , 1, 210-222		2
686	Echocardiography and Cardiovascular Function: Tools for the Next Decade. <i>Developments in Cardiovascular Medicine</i> , <b>1997</b> ,		
685	Relationship between left ventricular diastolic function and atrial natriuretic factor in never-treated mild hypertensives. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 946-50	2.3	7
684	How should we treat hypertensive women with cardiac and renal impairment?. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 242S-246S	2.3	4
683	Time course of regression of left ventricular hypertrophy after successful parathyroidectomy. <b>1997</b> , 121, 157-61		42
682	Incidence of cough induced by imidapril in patients with hypertension with enalapril-associated cough. <b>1997</b> , 58, 601-608		6
681	Blood pressure profile as a predictor of reversal of cardiovascular structural changes during antihypertensive treatment. <b>1997</b> , 58, 108-115		1
680	Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. <b>1997</b> , 30, 1802-8		28
679	Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. <i>American Journal of Hypertension</i> , <b>1997</b> , 10, 1064-8	2.3	39
678	Angiotensin II type-I receptor antagonists in the treatment of heart failure. <b>1997</b> , 62 Suppl 1, S13-7		4
677	Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists. <b>1997</b> , 19 Suppl A, 27-38		5
676	Angiotensin-converting enzyme gene polymorphism and cardiovascular endocrine system in coronary angiography patients. <i>International Heart Journal</i> , <b>1997</b> , 38, 799-810		14
675	Effects of ACE inhibitors versus calcium antagonists on left ventricular morphology and function in patients with essential hypertension. <b>1997</b> , 20, 7-10		5

- 674 Cardiac hypertrophy in diabetic spontaneously hypertensive rats: role of angiotensin II?. **1997**, 24, 445-8 6
- 673 Australian comparative outcome trial of angiotensin-converting enzyme inhibitor- and diuretic-based treatment of hypertension in the elderly (ANBP2): objectives and protocol. Management Committee on behalf of the High Blood Pressure Research Council of Australia. **1997**, 24, 188-92 39
- 672 New insights into the treatment of hypertension. **1997**, 24, 978-81
- 671 Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene. **1997**, 51, 1205-11 28
- 670 Signaling pathways in failing human heart muscle cells. **1997**, 7, 151-60 2
- 669 Comparison of left ventricular mass and geometric remodeling in treated and untreated men and women >50 years of age with systemic hypertension. **1997**, 80, 648-51 6
- 668 Evolution of left ventricular hypertrophy and function during long-term treatment of systemic hypertension with enalapril. **1997**, 79, 373-6 8
- 667 Molecular genetics of the renin-angiotensin system: implications for angiotensin II receptor blockade. **1997**, 75, 43-50 28
- 666 Meta-analysis of randomized trials: looking back and looking ahead. **1997**, 18, 594-601; discussion 661-6 26
- 665 Left ventricular mass assessed by three-dimensional echocardiography using rotational acquisition. **1997**, 20, 957-62 12
- 664 Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility. **1997**, 11, 27-32 6
- 663 Calcium channel blockers and hypertension: evolving perspective--1996. **1997**, 10 Suppl 3, 883-91 6
- 662 Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. **1998**, 12, 469-74 31
- 661 Absence of detectable regression of human hypertensive left ventricular hypertrophy following drug treatment for 1 year. **1998**, 25, 208-15 1
- 660 Decrease with age in frequency of the homozygous deletional angiotensin-converting enzyme genotype in hypertensive patients. **1998**, 25, 928-31 2
- 659 Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. **1998**, 123, 405-12 17
- 658 Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. **1998**, 12, 195-202 13
- 657 Plasma renin activity could be a useful predictor of left ventricular hypertrophy in essential hypertensives. **1998**, 12, 455-61 4

656	Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VENTricular hypertrophy Regression. <b>1998</b> , 12, 479-83		9
655	The importance of the renin-angiotensin system in cardiovascular disease. <b>1998</b> , 12, 295-9		81
654	Regression of LVH or improved prognosis (or both): what is the question?. <b>1998</b> , 12, 423-5		4
653	The heart in the hypertensive elderly. <b>1998</b> , 12, 593-7		6
652	Effects of losartan on hypertension and left ventricular mass: a long-term study. <b>1998</b> , 12, 505-10		71
651	Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy. <b>1998</b> , 12, 493-5		4
650	Differential effects of antihypertensive drugs with differing pharmacological properties on the basal ambulatory blood pressure. Japanese Ambulatory Pressure-ANTihypertensive Effects SEarching study group. <b>1998</b> , 12, 719-26		4
649	Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role?. <b>1998</b> , 40, 357-69		27
648	Signalling pathways for cardiac hypertrophy. <b>1998</b> , 10, 693-8		80
647	[Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations]. <b>1998</b> , 93, 733-7		3
646	Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. <b>1998</b> , 63, 229-35		41
645	[Aging and regression of cardiac hypertrophy in the hypertensive patient]. <b>1998</b> , 19, 870-7		
644	Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 263-71	2.3	22
643	Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 387-96	2.3	58
642	Individualized selection of antihypertensive drug therapy for older patients. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 62S-67S	2.3	4
641	Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 631-9	2.3	36
640	Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 697-707	2.3	21
639	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 1394-404	2.3	48

638	Biomolecular changes in the aging myocardium: the effect of enalapril. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 1297-304	2.3	34
637	Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months. <i>American Journal of Hypertension</i> , <b>1998</b> , 11, 1178-87	2.3	7
636	[Left ventricular diastolic function: physiology, physiopathology, evaluation, therapy, consequences of anesthesia]. <b>1998</b> , 17, 319-39		5
635	Regression of left ventricular hypertrophy with losartan potassium therapy in patients with hypertension. <b>1998</b> , 59, 819-825		3
634	Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patients. <b>1998</b> , 31, 1064-73		123
633	Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. <b>1998</b> , 31, 1635-40		178
632	Effects of Amlodipine and Lisinopril on Left Ventricular Mass and Diastolic Function in Previously Untreated Patients with Mild to Moderate Diastolic Hypertension. <b>1998</b> , 7, 109-117		14
631	Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. <b>1998</b> , 105, 275-315		77
630	The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal. <b>1998</b> , 55, 509-17		47
629	Differential Response in Left Ventricular Mass and Arterial Resistive Index following Fosinopril Therapy. <b>1998</b> , 15, 101-9		
628	[Current pharmaco-therapeutic strategies in the treatment of arterial hypertension]. <b>1998</b> , 56 Suppl 2, 11-21		
627	Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. <b>1998</b> , 7, 160-9		10
626	Carvedilol in the treatment of hypertension--a review of the clinical data base. <b>1998</b> , 47, 67-80		5
625	Integrins, adhesion, and cardiac remodeling. <b>1998</b> , 31, 176-80		48
624	Regression of Left Ventricular Wall Thickness during Ace-Inhibitor Treatment of Essential Hypertension is Associated with an Increase in Insulin Mediated Skeletal Muscle Blood Flow. <b>1998</b> , 7, 118-126		8
623	Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. <b>1998</b> , 98, 2037-42		164
622	Prognostic significance of serial changes in left ventricular mass in essential hypertension. <b>1998</b> , 97, 48-54		514
621	Pharmacologic Management of Chronic Heart Failure: A Review. <b>1998</b> , 2, 168-190		2

620	Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. <b>1998</b> , 31, 505-10	156
619	Cardiac hypertrophy and hypertension. <b>1998</b> , 7, 211-6	10
618	Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats. <b>1998</b> , 76, 431-4	8
617	Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca <sup>2+</sup> channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension. <b>1998</b> , 77, 79-87	5
616	Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. <b>1998</b> , 38, 477-91	6
615	Time Course of Complete Normalization of Left Ventricular Hypertrophy During Long-Term Antihypertensive Therapy With Angiotensin Converting Enzyme Inhibitors. <i>American Journal of Hypertension</i> , <b>1998</b> ,	2.3 0
614	Assessment of prevalence of left ventricular hypertrophy in hypertension. <b>1998</b> , 16, 715-23	36
613	Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth. <b>1998</b> , 16, 377-84	19
612	Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. <b>1998</b> , 16, 1515-22	18
611	Effect of treatment of isolated systolic hypertension on left ventricular mass. <b>1998</b> , 279, 778-80	34
610	Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy. <b>1998</b> , 62, 47-52	9
609	Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. <b>1998</b> , 62, 599-603	10
608	Changes of ischemic heart disease in Utsunomiya, Japan, over 10 years: a survey of primary care physicians. <b>1998</b> , 62, 675-9	3
607	Long-term effects of delapril hydrochloride on procollagen type III amino-terminal peptide, left ventricular mass and left ventricular function in hypertensive patients. <b>1998</b> , 62, 900-2	2
606	Cardiovascular ageing and heart failure. <b>1998</b> , 169, 480-4	8
605	Adrenoceptor blocking agents. <b>1998</b> , 168, 232-235	2
604	Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine. <b>1998</b> , 31, 32-8	27
603	[Captopril combined with hydrochlorothiazide in mild and moderate hypertension. A Brazilian multicenter study]. <b>1998</b> , 71, 713-6	1



602	Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it?. <b>1999</b> , 1, 327-36		16
601	Regional assessment of wall curvature and wall stress in left ventricle with magnetic resonance imaging. <b>1999</b> , 277, H901-10		23
600	Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. <b>1999</b> , 22, 17-22		60
599	Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension. <b>1999</b> , 20, 11-24		11
598	AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. <b>1999</b> , 20, 997-1008		63
597	Progression from hypertension to heart failure. Mechanisms and management. <b>1999</b> , 92 Suppl 1, 10-9; discussion 20-1		14
596	Clinical trials of single-drug therapy for the cardiac effects of hypertension. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 12S-18S	2.3	6
595	Insulin and diastolic dysfunction in lean and obese hypertensives: genetic influence. <b>1999</b> , 34, 1208-14		20
594	Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype?. <b>1999</b> , 84, 623-32		102
593	Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. <b>1999</b> , 99, 1991-6		86
592	State of the Art lecture. Risk mechanisms in hypertensive heart disease. <b>1999</b> , 34, 782-9		141
591	Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. <b>1999</b> , 34, 1041-6		51
590	Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?. <b>1999</b> , 47, 125-30		9
589	Fosinopril reduces left ventricular mass in untreated hypertensive patients: a controlled trial. <b>1999</b> , 47, 179-87		10
588	Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice. <b>1999</b> , 26, 206-11		5
587	Hyperglycaemia abolishes the antihypertrophic efficacy of bradykinin in rat ventricular myocytes. <b>1999</b> , 26, 519-21		5
586	Cardiac and vascular remodelling: effect of antihypertensive agents. <b>1999</b> , 13 Suppl 1, S35-41; discussion S49-50		4
585	Prediction of cardiovascular damage in hypertensive patients: clinic or ambulatory blood pressures?. <b>1999</b> , 13, 81-3		1

584	The influence of different antihypertensive drugs on left ventricular hypertrophy in a population sample of elderly men. <b>1999</b> , 13, 499-504	7
583	Antihypertensive agents and left ventricular hypertrophy with 'usual' care in the population setting. <b>1999</b> , 13, 497-8	3
582	The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. <b>1999</b> , 13, 511-6	17
581	The effect of nebivolol on left ventricular hypertrophy in hypertension. <b>1999</b> , 13, 549-51	6
580	Coronary artery blood flow: physiologic and pathophysiologic regulation. <b>1999</b> , 22, 775-86	35
579	Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. <b>1999</b> , 359, 394-9	26
578	Left ventricular hypertrophy: unresolved issues. <b>1999</b> , 1, 331-2	
577	Left Ventricular Hypertrophy. <b>1999</b> , 1, 219-230	4
576	Ambulatory blood pressure monitoring and echocardiography--noninvasive techniques for evaluation of the hypertensive patient. <b>1999</b> , 41, 397-440	12
575	Impact of hypertension and antihypertensive treatment on organ damage. <b>1999</b> , 84, 18K-24K	94
574	Long-term benefits of angiotensin II blockade: is the consensus changing?. <b>1999</b> , 84, 16S-21S	52
573	PREOPERATIVE EVALUATION OF HYPERTENSION: Anesthetic Implications in Patients With Coronary Disease. <b>1999</b> , 17, 549-565	1
572	Clinical implications of indapamide sustained release 1.5 mg in hypertension. <b>1999</b> , 37 Suppl 1, 21-32	7
571	Alpha 1-blockers in hypertension. <b>1999</b> , 15, 95-103	11
570	Nocturnal blood pressure reduction and development of left ventricular hypertrophy in patients with treated essential hypertension. <b>1999</b> , 10, 21-26	1
569	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 418-422	2-3
568	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 418-422	2-3 22
567	Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 1000-8	2-3 25

566	Diastolic function and tachycardia in hypertensive children. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 1009-14	2.3	28
565	Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 189S-194S	2.3	53
564	Hypertension and sudden cardiac death. <i>American Journal of Hypertension</i> , <b>1999</b> , 12, 181S-188S	2.3	62
563	Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. <b>1999</b> , 34, 125-34		650
562	Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. <b>1999</b> , 353, 611-6		1650
561	Hormones and hemodynamics in heart failure. <b>1999</b> , 341, 577-85		906
560	Prevention of coronary heart disease. Part I. Primary prevention. <b>1999</b> , 45, 497-571		8
559	Epidemiology of risk factors for hypertension: implications for prevention and therapy. <b>1999</b> , 57, 695-712		30
558	Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension. <b>1999</b> , 33, 1677-84		4
557	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). <b>1999</b> , 33, 2092-197		482
556	Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group. <b>1999</b> , 137, 118-25		6
555	Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. <b>1999</b> , 106, 544-9		63
554	Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. <b>1999</b> , 91 Suppl 1, 8-13		8
553	Discussion and Debate. <b>1999</b> , 92, 7-9		
552	Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. <b>1999</b> , 92, 110-4		27
551	Turning up the heat on hypertension. It's time to be more aggressive in finding and treating this silent killer. <b>1999</b> , 105, 82-4, 89-93		2
550	Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. <b>1999</b> , 17, 53-60		17
549	Insertion/deletion angiotensin converting enzyme gene polymorphism affects the microvascular structure of the kidney in patients with nondiabetic renal disease. <b>1999</b> , 17, 351-6		12

548	Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention. <b>1999</b> , 17, 1323-8	5
547	Effect of insulin resistance on left ventricular hypertrophy and dysfunction in essential hypertension. <b>1999</b> , 17, 1153-60	38
546	Differential suppression of pressure-overload cardiac and aortic hypertrophy in rats by angiotensin-converting enzyme inhibitors. <b>1999</b> , 80, 333-42	4
545	When Antihypertensive Monotherapy Fails. <b>2000</b> , 93, 548-556	6
544	Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. <b>2000</b> , 47, 57-67	27
543	Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. <b>2000</b> , 18, 1465-75	126
542	Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. <b>2000</b> , 57, 2634-43	77
541	Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. <b>2000</b> , 58, 889-97	69
540	The modern treatment of hypertension. <b>2000</b> , 14 Suppl 1, S51-62	2
539	Angiotensin II receptor antagonists in arterial hypertension. <b>2000</b> , 14 Suppl 1, S69-72	
538	Chymase-dependent angiotensin II formation in human blood vessels. <b>2000</b> , 14, 373-6	6
537	Hypertension and the heart. <b>2000</b> , 14, 597-604	63
536	Blocking the tissue renin-angiotensin system: the future cornerstone of therapy. <b>2000</b> , 14 Suppl 2, S23-31	7
535	Hypertension drug trials: past, present, and future. <b>2000</b> , 14, 729-38	5
534	Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. <b>2000</b> , 135, 353-9	27
533	Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. <b>2000</b> , 14, 427-32	71
532	Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy. <b>2000</b> , 14, 61-6	6
531	Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats. <b>2000</b> , 14, 533-42	17

530	Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy. <b>2000</b> , 2, 260-70	
529	Myocardial renin is neither necessary nor sufficient to initiate or maintain ventricular hypertrophy. <b>2000</b> , 278, R578-86	10
528	The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. <b>2000</b> , 23, 317-22	14
527	Role of angiotensin-converting-enzyme inhibitors in the treatment of hypertension. <b>2000</b> , 57 Suppl 1, S8-11	8
526	Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. <b>2000</b> , 36, 220-5	190
525	Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). <b>2000</b> , 51, 131-9	19
524	Angiotensin converting enzyme inhibition: from viper to patient. <b>2000</b> , 84 Suppl 1, i11-4:discussion i50	7
523	Left ventricular hypertrophy is associated with an attenuated endothelium-dependent vasodilation in hypertensive men. <b>2000</b> , 9, 309-14	18
522	Treatment of Hypertension in the Institutionalized Elderly. <b>2000</b> , 9, 34-41	
521	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?. <b>2000</b> , 21, 1653-65	84
520	Left ventricular mass and global function in essential hypertension after antihypertensive therapy. <b>2000</b> , 28, 9-19	14
519	Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. <b>2000</b> , 36, 766-73	84
518	Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. <b>2000</b> , 102, 1388-93	508
517	Left ventricular hypertrophy: pathogenesis, detection, and prognosis. <b>2000</b> , 102, 470-9	786
516	Induction of angiotensin-converting enzyme by oncostatin m in human endothelial cells. <b>2000</b> , 12, 1253-6	9
515	Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. <b>2000</b> , 32, 697-709	59
514	Endothelial dysfunction limits the antihypertrophic action of bradykinin in rat cardiomyocytes. <b>2000</b> , 32, 1119-26	16
513	Therapeutic options in minimizing left ventricular hypertrophy. <b>2000</b> , 139, S9-14	31

512	Autonomic imbalance, hypertension, and cardiovascular risk. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, 112S-122S	2.3	148
511	Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, 776-82	2.3	40
510	Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , <b>2000</b> , 13, 1149-54	2.3	35
509	Chronic losartan treatment decreases angiotensin II-mediated facilitation of noradrenaline release in the caudal artery of spontaneously hypertensive rats. <b>2000</b> , 67, 3153-62		6
508	Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: A randomized, double-blind study. <b>2000</b> , 61, 331-338		7
507	Left ventricular hypertrophy and angiotensin-converting enzyme gene polymorphism in renal allograft recipients. <b>2000</b> , 32, 542-4		3
506	Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. <b>2000</b> , 356, 359-65		747
505	The fixed combination of verapamil SR/trandolapril. <b>2000</b> , 1, 515-35		3
504	Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. <b>2000</b> , 2, 101-10		12
503	Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. <b>2000</b> , 9, 140-5		22
502	Lack of Association of Angiotensin-converting Enzyme and Angiotensinogen Genes Polymorphisms with Left Ventricular Structure in Young Normotensive Men. <b>2000</b> , 9, 47-51		13
501	Organ damage in treated middle-aged hypertensives compared to normotensives: results from a cross-sectional study in general practice. <b>2000</b> , 9, 28-33		9
500	[Relationship between cardiovascular risk profile and anti-hypertensive drug use. GEDEC (Spanish group of cardiovascular studies)]. <b>2000</b> , 115, 41-5		15
499	[Hypertension in the elderly and health global results with different pharmacological therapies]. <b>2000</b> , 26, 533-41		3
498	[Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?]. <b>2000</b> , 115, 178-80		3
497	[Do angiotensin II receptor antagonists substitute angiotensin converting enzyme inhibitors in the treatment of high blood pressure?]. <b>2000</b> , 53, 4-12		0
496	Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension. <b>2000</b> , 59, 141-57		24
495	Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. <b>2000</b> , 36, 438-43		190

494	Cytoplasmic signaling pathways that regulate cardiac hypertrophy. <b>2001</b> , 63, 391-426		561
493	Perindopril: an updated review of its use in hypertension. <b>2001</b> , 61, 867-96		48
492	Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. <b>2001</b> , 37, 293-9		70
491	Prognostic significance of endothelial dysfunction in hypertensive patients. <b>2001</b> , 104, 191-6		901
490	Pediatric hypertension. <b>2001</b> , 142, 422-32		34
489	Angiotensin-converting enzyme inhibitors. <b>2001</b> , 56, 13-75		44
488	Left ventricular hypertrophy and angiotensin II antagonists. <i>American Journal of Hypertension</i> , <b>2001</b> , 14, 174-82	2.3	60
487	Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. <i>American Journal of Hypertension</i> , <b>2001</b> , 14, 775-82	2.3	36
486	Sibling correlation of left ventricular mass and geometry in hypertensive African Americans and whites: the HyperGEN study. Hypertension Genetic Epidemiology Network. <i>American Journal of Hypertension</i> , <b>2001</b> , 14, 1226-30	2.3	60
485	Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: an open-label, multicenter trial. <b>2001</b> , 62, 261-271		2
484	Effect of controlled-release nifedipine on left ventricular hypertrophy in Japanese patients with hypertension: An open-label, uncontrolled study. <b>2001</b> , 62, 773-782		2
483	Beta-adrenergic blocking drugs in the treatment of hypertension. <b>2001</b> , 10, 366-86		56
482	Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. <b>2001</b> , 10, 101-10		20
481	Effects of antihypertensive agents on the left ventricle: clinical implications. <b>2001</b> , 1, 263-79		18
480	Behavioral treatment of hypertensive heart disease in African Americans: rationale and design of a randomized controlled trial. <b>2001</b> , 27, 83-95		11
479	Guidelines for the management of hypertension for general practitioners. <b>2001</b> , 24, 613-34		109
478	Angiotensin II-receptor blockers: clinical relevance and therapeutic role. <b>2001</b> , 58, 671-83		36
477	Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. <b>2001</b> , 280, H885-91		47

476	Left ventricular changes in isolated office hypertension: a blood pressure-matched comparison with normotension and sustained hypertension. <b>2001</b> , 161, 2677-81	23
475	Surrogate End Points of Antihypertensive Treatment: Left Ventricular Hypertrophy and Structural Alteration of Carotid Arteries. <b>2001</b> , 1, 89-95	2
474	Regression of Left Ventricular Hypertrophy and Improved Prognosis. <b>2001</b> , 104, 1582-1584	21
473	Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. <b>2001</b> , 19, 303-9	89
472	Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. <b>2001</b> , 19, 1001-6	71
471	Regression of left ventricular hypertrophy in human hypertension with irbesartan. <b>2001</b> , 19, 1167-76	127
470	Inhibitory effect of the angiotensin converting enzyme inhibitors captopril and enalapril on the conversion of procollagen to collagen. <b>2001</b> , 19, 1835-9	15
469	Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. <b>2001</b> , 72, 107-11	56
468	Effect of cilnidipine on left ventricular diastolic function in hypertensive patients as assessed by pulsed Doppler echocardiography and pulsed tissue Doppler imaging. <b>2001</b> , 65, 305-9	19
467	High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. <b>2001</b> , 24, 99-104	24
466	The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension. <b>2001</b> , 3, 511-8	7
465	Meta-analyses of antihypertensive therapy: Are some of them misleading?. <b>2001</b> , 3, 381-6	5
464	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. <b>2001</b> , 21, 196-207	6
463	Spatial and temporal analysis of left ventricular filling flow propagation in hypertensive patients before and after regression of myocardial hypertrophy with alacepril therapy. <b>2001</b> , 18, 479-83	
462	Angiotensin II: a proven therapeutic target with some mechanistic mysteries. <b>2001</b> , 10, 45-7	
461	Angiotensin receptor blockers: evidence for preserving target organs. <b>2001</b> , 24, 183-90	32
460	Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. <b>2001</b> , 24, 603-7	18
459	Commentary on treatment of hypertension in the elderly. <b>2001</b> , 15, 281-2	4



458	Effect of Amlodipine on Echocardiographic Variables in Cats with Systemic Hypertension. <b>2001</b> , 15, 52-56	52
457	Right atrial function in hypertensive patients: effects of antihypertensive therapy. <b>2001</b> , 15, 463-70	8
456	The ECG and left ventricular hypertrophy in primary care hypertensives. <b>2001</b> , 15, 215-7	3
455	Angiotensin II and the pathophysiology of cardiovascular remodeling. <b>2001</b> , 87, 10C-17C	71
454	Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. <b>2001</b> , 2, 227-32	8
453	Regression of cardiac hypertrophy in the SHR by combined renin-angiotensin system blockade and dietary sodium restriction. <b>2001</b> , 2, S148-S153	2
452	Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. <b>2001</b> , 103, 836-41	103
451	Downregulation of angiotensin-converting enzyme by tumor necrosis factor-alpha and interleukin-1beta in cultured human endothelial cells. <b>2001</b> , 38, 370-8	33
450	Antihypertensive drug therapies and the risk of ischemic stroke. <b>2001</b> , 161, 37-43	46
449	Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. <b>2001</b> , 161, 965-71	61
448	Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. <b>2001</b> , 104, 1248-54	181
447	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. <b>2001</b> , 29, 13-21	122
446	Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. <b>2001</b> , 24, 2091-6	200
445	Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. <b>2001</b> , 10, 288-98	13
444	Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. <b>2001</b> , 10, 74-82	97
443	Assessment of left ventricular mass by cardiovascular magnetic resonance. <b>2002</b> , 39, 750-5	220
442	Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP. <b>2002</b> , 40, 498-503	31
441	Relationship between treatment-induced changes in left ventricular mass and blood pressure in black african hypertensive patients: results of the Baragwanath Trial. <b>2002</b> , 105, 830-6	16

440	Regression of left ventricular hypertrophy: hoping for a longer life. <b>2002</b> , 3, 141-4	4
439	Angiotensin II receptor antagonists role in arterial hypertension. <b>2002</b> , 16 Suppl 1, S93-9	55
438	Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. <b>2002</b> , 23, 1963-71	49
437	The drive to identify genetic factors influencing left ventricular mass responses to antihypertensive treatment. <b>2002</b> , 20, 583-5	2
436	Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. <b>2002</b> , 16, 133-40	42
435	Relationship between left ventricular mass and blood pressure in treated hypertension. <b>2002</b> , 16, 61-6	24
434	Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. <b>2002</b> , 13, 1733-9	158
433	Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. <b>2002</b> , 40, 673-8	132
432	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. <b>2002</b> , 288, 1491-8	306
431	Left Ventricular Hypertrophy in Hypertension. <b>2002</b> , 2, 251-265	
430	Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. <b>2002</b> , 20, 657-63	48
429	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. <b>2002</b> , 20, 1445-50	63
428	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. <b>2002</b> , 20, 1855-64	90
427	Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. <b>2002</b> , 20, 2293-300	90
426	Proliferative signaling and disease progression in heart failure. <b>2002</b> , 66, 225-31	19
425	Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. <b>2002</b> , 64, 196-200	14
424	Should beta blockers be used in the treatment of hypertension in the elderly?. <b>2002</b> , 4, 286-94	7
423	Downregulation of angiotensin converting enzyme by TNF-alpha in differentiating human macrophages. <b>2002</b> , 18, 304-10	10

422	What is the appropriate treatment of hypertension in elders?. <b>2002</b> , 57, M483-6		34
421	Risk-benefit assessment of angiotensin II receptor antagonists. <b>2002</b> , 1, 137-52		2
420	Antagonistas de los receptores de la angiotensina II. Una revisi3n farmacoterap3utica. <b>2002</b> , 19, 129-138		
419	Systolic hypertension as a cardiovascular risk factor. <b>2002</b> , 11, 134-43		8
418	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <b>2002</b> , 359, 995-1003		4163
417	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. <b>2002</b> , 144, 1057-64		57
416	The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 66-71	2.3	83
415	Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 22S-27S	2.3	15
414	ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 367-71	2.3	17
413	Antihypertensive effects of angiotensin converting enzyme inhibition by lisinopril in post-transplant patients. <i>American Journal of Hypertension</i> , <b>2002</b> , 15, 911-6	2.3	9
412	A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizaci3n Ambulatoria Presi3n Arterial APROVEL). <b>2002</b> , 24, 126-38		33
411	Antihypertensive effects of aerobic exercise in middle-aged normotensive men with exaggerated blood pressure response to exercise. <b>2002</b> , 25, 507-14		19
410	Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy. <b>2002</b> , 25, 865-73		9
409	Perindopril reverses myocyte remodeling in the hypertensive heart. <b>2002</b> , 25, 85-90		13
408	Left Ventricular Hypertrophy in Hypertension. <b>2002</b> , 2, 142-156		2
407	Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. <b>2002</b> , 40, 1153-61		87
406	Hypertension, left ventricular hypertrophy, and sudden death. <b>2002</b> , 4, 449-57		41
405	Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?. <b>2002</b> , 4, 474-8		22

404	Left ventricular hypertrophy in chronic renal failure patients. <b>2002</b> , 7, S64-S66		
403	Efficacy of very low dose perindopril 2 mg/indapamide 0.625 mg combination on left ventricular hypertrophy in hypertensive patients: the P.I.C.X.E.L. study rationale and design. <b>2002</b> , 16, 653-9		11
402	Left ventricular hypertrophy in chronic renal failure patients. <b>2002</b> , 7, S64-S66		0
401	Trials in isolated systolic hypertension: an update. <b>2003</b> , 5, 427-34		1
400	Trials in isolated systolic hypertension: an update. <b>2003</b> , 5, 329-36		7
399	Regression of left ventricular hypertrophy: are there preferred drugs?. <b>2003</b> , 5, 368-71		5
398	[Regression of left ventricular hypertrophy in hypertensive heart disease]. <b>2003</b> , 28, 764-78		1
397	Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. <b>2003</b> , 28, 744-53		35
396	Active subgroup mining: a case study in coronary heart disease risk group detection. <b>2003</b> , 28, 27-57		59
395	Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. <b>2003</b> , 91, 9G-14G		159
394	Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. <b>2003</b> , 145, 993-8		22
393	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. <b>2003</b> , 115, 41-6		574
392	Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial. <b>2003</b> , 64, 422-33		5
391	Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction. A 1-year clinical study comparing the effects of amlodipine and nifedipine retard on ambulatory blood pressure and left ventricular systolic function in Chinese hypertensive type 2 diabetic patients. <b>2003</b> , 69, 159-66		9
390	Different drug classes have variable effects on blood pressure depending on the time of day. <i>American Journal of Hypertension</i> , <b>2003</b> , 16, 46-50	2.3	28
389	A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. <b>2003</b> , 348, 583-92		903
388	ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. <b>2003</b> , 3, 351-60		8
387	Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. <b>2003</b> , 4, 234-43		13

386	Glitazones and heart failure: critical appraisal for the clinician. <b>2003</b> , 107, 1350-4		79
385	ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. <b>2003</b> , 4, 74-9		4
384	The ALLHAT trial: strengths and limitations. <b>2003</b> , 21, 229-32		11
383	Neue Behandlungsstrategien bei Herzinsuffizienz - Stufentherapie dem klinischen Stadium entsprechend. <b>2003</b> , 29, 453-461		
382	End-organ damage: does it really matter how we prevent it?. <b>2003</b> , 5, F33-F39		
381	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. <b>2003</b> , 5, A43-A48		18
380	Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , <b>2003</b> , 42, 622-8	3.1	33
379	Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. <b>2003</b> , 21, 217-21		18
378	Left ventricular hypertrophy regression with antihypertensive treatment: focus on Candesartan. <b>2003</b> , 2, 5-15		8
377	Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. <i>International Heart Journal</i> , <b>2003</b> , 44, 693-704		12
376	Left ventricular regional variations in myosin isoform shift in Dahl salt-sensitive hypertensive rats. <b>2003</b> , 26, 251-5		2
375	Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. <b>2004</b> , 286, H2096-102		17
374	Recent insights in the development of organ damage caused by hypertension. <b>2004</b> , 59, 369-81		11
373	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. <b>2004</b> , 292, 2343-9		472
372	Diet and the prevention of coronary heart disease. <b>2004</b> , 21-55		0
371	Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. <b>2004</b> , 109, 2492-9		165
370	Left ventricle mass index and the common, functional, X-linked angiotensin II type-2 receptor gene polymorphism (-1332 G/A) in patients with systemic hypertension. <b>2004</b> , 43, 1189-94		33
369	Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function. <b>2004</b> , 55, 669-78		5

368	Surrogate markers for cardiovascular disease: structural markers. <b>2004</b> , 109, IV22-30	146
367	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. <b>2004</b> , 110, 1456-62	379
366	Valsartan. <b>2004</b> , 2, 67-101	
365	Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice. <b>2004</b> , 26, 644-57	12
364	Left ventricular hypertrophy after renal transplantation: new approach to a deadly disorder. <b>2004</b> , 19, 1682-6	29
363	Primary hyperparathyroidism and heart disease--a review. <b>2004</b> , 25, 1776-87	209
362	Sympathetic hyperactivity in chronic renal failure: a wake-up call. <b>2004</b> , 15, 524-37	164
361	Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. <b>2004</b> , 43, 731-8	239
360	Early target organ damage and its reversibility: the heart. <b>2004</b> , 26, 673-87	12
359	Evidence for altered ETB receptor characteristics during development and progression of ventricular cardiomyocyte hypertrophy. <b>2004</b> , 287, H425-32	5
358	Echocardiographic Assessment of Left Ventricular Structure in Hypertension and the Impact on Clinical Outcomes. <b>2004</b> , 20, 304-314	1
357	Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. <b>2004</b> , 66, 158-65	92
356	The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients. <b>2004</b> , 6, 195-9	5
355	Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. <b>2004</b> , 8, 320-7	39
354	Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. <b>2004</b> , 18, 53-9	36
353	Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. <b>2004</b> , 18, 403-9	40
352	Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study). <b>2004</b> , 18, 417-22	16
351	beta-Blockers in hypertension: is carvedilol different?. <b>2004</b> , 93, 7B-12B	55

350	RAAS inhibitors in the cardiovascular continuum: what is still missing?. <b>2004</b> , 18, 311-20	2
349	Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). <b>2004</b> , 27, 169-73	9
348	Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. <b>2004</b> , 21, 76-86	18
347	Clinical physiology and pharmacology conference: a nonpharmacological, evidence based medical approach using exercise method to lower and maintain blood pressure control in the elderly. <b>2004</b> , 36, 473-6	1
346	Antihypertensive drugs and the heart. <b>2004</b> , 6, 409-15	2
345	Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. <b>2004</b> , 4, 269-80	28
344	Reversal of left ventricular hypertrophy: what have recent trials taught us?. <b>2004</b> , 4, 369-78	8
343	Los diuréticos son los fármacos de primera elección en el tratamiento de la hipertensión arterial. <b>2004</b> , 21, 466-474	
342	Atrial fibrillation: guiding lessons from epidemiology. <b>2004</b> , 22, 1-8	6
341	Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography. <b>2004</b> , 17, 56-61	33
340	Evolución clínica y reversibilidad de la disfunción sistólica en pacientes con miocardiopatía dilatada hipertensiva e insuficiencia cardíaca crónica. <b>2004</b> , 57, 834-841	4
339	Clinical Outcome and Reversibility of Systolic Dysfunction in Patients With Dilated Cardiomyopathy Due to Hypertension and Chronic Heart Failure. <b>2004</b> , 57, 834-841	1
338	Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?. <b>2004</b> , 43, 2216-8	6
337	Negative regulators of cardiac hypertrophy. <b>2004</b> , 63, 500-9	97
336	Hypertensive heart disease: effects of lifestyle modifications and antihypertensive drug treatment. <b>2004</b> , 2, 617-25	2
335	Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance. <b>2004</b> , 53, 777-81	36
334	Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. <b>2004</b> , 97, 383-8	43
333	Marinobufagenin may mediate the impact of salty diets on left ventricular hypertrophy by disrupting the protective function of coronary microvascular endothelium. <b>2004</b> , 62, 993-1002	3

332	Effect of different antihypertensive drug classes on central aortic pressure. <i>American Journal of Hypertension</i> , <b>2004</b> , 17, 118-23	2-3	241
331	Valsartan. <b>2004</b> , 2, 67-101		2
330	Carvedilol inhibits basal and stimulated ACE production in human endothelial cells. <i>Journal of Cardiovascular Pharmacology</i> , <b>2004</b> , 43, 616-21	3-1	11
329	What lies behind the intense criticism of ALLHAT?. <b>2004</b> , 22, 223-4; author reply 224-7		1
328	Long-term oral treatment with nicorandil prevents the progression of left ventricular hypertrophy and preserves viability. <i>Journal of Cardiovascular Pharmacology</i> , <b>2005</b> , 45, 333-40	3-1	5
327	Regression of left ventricular hypertrophy with moexipril, an angiotensin-converting enzyme inhibitor, in hypertensive patients. <b>2005</b> , 12, 3-8		6
326	Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. <b>2005</b> , 23, 2063-70		75
325	Left ventricular hypertrophy as a predictor of cardiovascular risk. <b>2005</b> , 23, S27-33		92
324	Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. <b>2005</b> , 15, 75-81		24
323	Prospective study of the changes in left ventricular mass and geometry patterns in hypertensive patients During 5 years of follow-up. <b>2005</b> , 69, 1374-9		8
322	Further evidence for low-dose combinations in patients with left ventricular hypertrophy. <b>2005</b> , 19 Suppl 1, S9-14		3
321	The cardiovascular implications of hypokalemia. <b>2005</b> , 45, 233-47		39
320	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. <b>2005</b> , 48, 1980-7		32
319	Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. <b>2005</b> , 12, 409-20		63
318	Biomedical Vignette. <b>2005</b> , 12, 249-253		
317	Cardiovascular Risk Factors in the Elderly. <b>2005</b> , 79-102		
316	Cardiovascular Disease in the Elderly. <b>2005</b> ,		
315	Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells. <b>2005</b> , 289, H2000-4		20



314	[Cardioprotective effects of anti-hypertensive medications]. <b>2005</b> , 21 Suppl 5, S17-21	
313	Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. <b>2005</b> , 33 Suppl 1, 21A-29A	9
312	The potential advantage of omapatrilat: dual anti-fibrotic and anti-inflammatory effects in one single molecule. <b>2005</b> , 23, 273-5	1
311	Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice. <b>2005</b> , 15, 57-67	43
310	A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. <b>2005</b> , 32, 30-43	6
309	Eplerenone: a review of its use in essential hypertension. <b>2005</b> , 5, 51-69	24
308	Benefits of Diuretic-Based Low-Cost Antihypertensive Therapy. <b>2005</b> , 12, 73-78	
307	Role of angiotensin II in the evolution of diastolic heart failure. <b>2005</b> , 7, 740-7	24
306	Marinobufagenin may mediate the impact of salty diets on left ventricular hypertrophy by disrupting the protective function of coronary microvascular endothelium. <b>2005</b> , 64, 854-63	2
305	Prognostic value of electrocardiographic criteria for left ventricular hypertrophy. <b>2005</b> , 150, 161-7	83
304	Hypertensive heart disease. <b>2005</b> , 28, 191-202	97
303	Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension. <b>2005</b> , 25, 367-75	4
302	Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients. <b>2006</b> , 15, 107-15	5
301	The prevention of myocardial ultrastructural changes by perindopril, atenolol and amlodipine in chronic alcohol administered rats. <b>2006</b> , 53, 142-8	6
300	Calcium channel blockers in the spectrum of antihypertensive agents. <b>2006</b> , 7, 2385-401	8
299	Association between levels of blood pressure and measures of subclinical disease multi-ethnic study of atherosclerosis. <i>American Journal of Hypertension</i> , <b>2006</b> , 19, 1110-7	2-3 30
298	Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. <b>2006</b> , 8, 487-92	17
297	Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. <b>2006</b> , 8, 634-41	39

296	Effects of salt loading and various therapies on cardiac hypertrophy and fibrosis in young spontaneously hypertensive rats. <b>2006</b> , 79, 838-46	8
295	Impact of left ventricular hypertrophy late after aortic valve replacement for aortic stenosis on cardiovascular morbidity and mortality. <b>2006</b> , 109, 41-7	20
294	The Association Between Inflammatory Markers and Hypertension. A Call for Anti-Inflammatory Strategies?. <b>2006</b> , 6, 1262-1273	
293	. <b>2006</b> ,	1
292	Antihypertensive and Cardiovascular Effects of Combined Blockade of Renin-Angiotensin System with ACE Inhibitor and Angiotensin II Type 1 Receptor Blocker in Hypertensive Patients: A 24-Week Randomized Controlled Double-Dummy Trial. <i>Heart International</i> , <b>2006</b> , 2, 182618680600200	0.3
291	THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL. <b>2006</b> , 2, 9-17	
290	Management of Diastolic Dysfunction. 250-265	
289	Angiotensin-converting enzyme inhibitors influence left ventricular mass and function independently of the antihypertensive effect. <i>Journal of Cardiovascular Pharmacology</i> , <b>2006</b> , 48, 207-11 <sup>3.1</sup>	6
288	Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?. <b>2006</b> , 33, 159-66	45
287	Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. <b>2002</b> , 20, 93-110	18
286	Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. <b>2006</b> , 36, 713-9	72
285	How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. <b>2006</b> , 20, 398-406	7
284	Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition. <b>2006</b> , 29, 277-84	54
283	Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle. <b>2006</b> , 29, 89-94	4
282	Left ventricular mass and heart sympathetic activity after renal transplantation in children and young adults. <b>2006</b> , 21, 1413-8	12
281	From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. <b>2006</b> , 48, 326-41	208
280	Left ventricular geometric patterns in newly presenting Nigerian hypertensives: an echocardiographic study. <b>2006</b> , 6, 4	21
279	From hypertension to heart failure -- are there better primary prevention strategies?. <b>2006</b> , 7, 64-73	29

278	Calcium-channel modulators for cardiovascular disease. <b>2006</b> , 11, 49-73	16
277	Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. <b>2007</b> , 5, 451-61	4
276	Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. <b>2007</b> , 13, 229-39	10
275	Left ventricular hypertrophy: a shift in paradigm. <b>2007</b> , 14, 157-71	33
274	The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection. <b>2007</b> , 3, 57-64	1
273	Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. <b>2007</b> , 8, 480-6	24
272	High salt intake: a cause of blood pressure-independent left ventricular hypertrophy?. <b>2007</b> , 22, 2426-9	27
271	Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. <b>2007</b> , 30, 307-13	26
270	Use of predictive markers to improve cardiovascular protection. <b>2007</b> , 3, 447-56	1
269	Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects. <b>2007</b> , 3, 769-80	3
268	Cardiothoracic ratio within the "normal" range independently predicts mortality in patients undergoing coronary angiography. <b>2007</b> , 93, 491-4	24
267	Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension. <b>2007</b> , 3, 196-202	
266	Cardiovascular drug therapy in the elderly. <b>2007</b> , 15, 195-215	26
265	Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment. <b>2007</b> , 12, 87-94	3
264	How Can the Mortality Rate of Chronic Dialysis Patients Be Reduced?. <b>2007</b> , 6, 97-100	
263	What are the Unique Aspects of Antihypertensive Therapy in Dialysis Patients?. <b>2007</b> , 7, 170-180	
262	Family history of hypertension influences left ventricular diastolic function during chronic antihypertensive therapy. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, 410-5	2.3
261	Benefits of First-Line Combination of Perindopril and Indapamide in Clinical Practice for Patients With Hypertension and Diabetes. <i>American Journal of Hypertension</i> , <b>2007</b> , 20, S9-S14	2.3 4

260	Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. <b>2007</b> , 369, 2079-87	269
259	Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. <b>2007</b> , 30, 489-96	95
258	Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?. <b>2007</b> , 16, 6-12	9
257	Diuretic Therapy in Cardiovascular Disease. <b>2007</b> , 213-230	2
256	Angiotensin-Converting Enzyme Inhibitors. <b>2007</b> , 985-1001	
255	Statins: a perspective for left ventricular hypertrophy treatment. <b>2007</b> , 37, 681-91	25
254	Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension. <b>2007</b> , 15, 295-8	12
253	Calcium signaling phenomena in heart diseases: a perspective. <b>2007</b> , 298, 1-40	30
252	Anti-inflammatory actions of quinapril. <b>2007</b> , 21, 211-20	5
251	Heart failure and cardiac hypertrophy. <b>2007</b> , 9, 289-301	18
250	Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy. <b>2008</b> , 26, 346-51	30
249	Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. <b>1993</b> , 44, 292-7	77
248	Update of the French Society of Cardiology recommendations on indications for Doppler echocardiography published in 1999. <b>2008</b> , 101, 249-89	12
247	Hypertension. <b>2008</b> , 101, 250-254	
246	Organic valve diseases. <b>2008</b> , 101, 254-264	
245	Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. <b>2008</b> , 2, 165-72	46
244	Treatment of hypertension in heart failure with preserved ejection fraction: role of the kidney. <b>2008</b> , 4, 479-503	
243	Arterial Hypertension and Cardiac Damage. <b>2008</b> , 15, 141-170	9

242	Shp shape: FAKs about hypertrophy. <b>2008</b> , 103, 776-8		2
241	Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. <i>American Journal of Hypertension</i> , <b>2008</b> , 21, 248-56	2.3	10
240	Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. <i>American Journal of Hypertension</i> , <b>2008</b> , 21, 231-7	2.3	22
239	EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY. <b>2008</b> , 4, 67-75		
238	Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention. <i>Vascular Health and Risk Management</i> , <b>2008</b> , Volume 4, 67-73	4.4	9
237	ACE INHIBITORS IN ARTERIAL HYPERTENSION TREATMENT: FOCUS ON LISINOPRIL. <b>2009</b> , 5, 57-62		2
236	INNOVATIVE ANTIHYPERTENSIVE THERAPY IN THE LIGHT OF COMPLETED CLINICAL TRIALS. <b>2009</b> , 5, 89-97		
235	Correlation of myocardial interstitial collagen in the right ventricular septum with ventricular function of patients with ischemic cardiomyopathy. <b>2009</b> , 92, 54-62		3
234	Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. <b>2009</b> , 119, 530-7		243
233	Dietary sodium alters the prevalence of electrocardiogram determined left ventricular hypertrophy in hypertension. <i>American Journal of Hypertension</i> , <b>2009</b> , 22, 669-73	2.3	17
232	Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. <b>2009</b> , 54, 1084-91		217
231	Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography. <b>2009</b> , 32, 895-900		16
230	Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction. <b>2009</b> , 296, R672-80		27
229	Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. <b>2009</b> , 54, 731-7		26
228	Clinical impact of left ventricular hypertrophy and implications for regression. <b>2009</b> , 52, 153-67		117
227	Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients. <b>2009</b> , 42, 584-8		22
226	Understanding heart failure with preserved ejection fraction: clinical importance and future outlook. <b>2009</b> , 15, 186-92		5
225	Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. <b>2009</b> , 104, 359-65		11

224	Risks of electrocardiographic left ventricular hypertrophy in hypertensive individuals and benefits of treatment-induced regression. <b>2009</b> , 3, 247-254		
223	Beta-adrenergic antagonists in hypertension: a review of the evidence. <b>2009</b> , 43, 2031-43		13
222	Additional salutary effects of the combination of exercise training and an angiotensin-converting enzyme inhibitor on the left ventricular function of spontaneously hypertensive rats. <b>2009</b> , 27, 1309-16		4
221	Cardiac dysfunction after renal transplantation; incomplete resolution in pediatric population. <b>2009</b> , 87, 1737-43		12
220	Chronic kidney disease: a marker of cardiovascular disease. <b>2009</b> , 5, 24-9		6
219	B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target. <b>2009</b> , 9, 814-25		28
218	Association and prognostic impact of persistent left ventricular hypertrophy after live-donor kidney transplantation: a prospective study. <b>2010</b> , 14, 68-74		6
217	Anti-hypertensive drugs and left ventricular hypertrophy: a clinical update. <b>2010</b> , 5, 469-79		12
216	Role of the renin-angiotensin system in cardiovascular disease. <b>2010</b> , 24, 341-4		21
215	Ace gene dosage influences the development of renovascular hypertension. <b>2010</b> , 37, 490-5		6
214	THE EYE [MIRROR OF CARDIOVASCULAR DISORDERS. EVOLUTION OF PERCEPTION ABOUT HYPERTENSIVE RETINOPATHY. <b>2010</b> , 6, 853-858		0
213	Diagnosis and Management of Coronary Artery Disease. <b>2010</b> , 286-294		
212	Left ventricular hypertrophy, geometric patterns and clinical correlates among treated hypertensive Nigerians. <i>Pan African Medical Journal</i> , <b>2010</b> , 4, 8	1.2	9
211	Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. <i>American Journal of Hypertension</i> , <b>2010</b> , 23, 786-93	2.3	12
210	A prediction model for left ventricular mass in patients at high cardiovascular risk. <b>2010</b> , 17, 621-7		9
209	Differences in determinants of left ventricular mass assessed by cardiac magnetic resonance imaging across subjects with and without previous symptomatic atherosclerotic disease. <b>2010</b> , 138, 145-50		2
208	The restoration of chronotropic competence in heart failure patients with normal ejection fraction (RESET) study: rationale and design. <b>2010</b> , 16, 17-24		36
207	Importance of blood pressure control in left ventricular mass regression. <b>2010</b> , 4, 302-10		20

206	Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. <b>2010</b> , 32, 903-12	18
205	Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure--are they important for doctors?. <b>2011</b> , 63, 740-51	7
204	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society	325
203	How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study. <b>2011</b> , 104, 343-51	18
202	Cardiovascular drug therapy in the elderly: benefits and challenges. <b>2011</b> , 8, 13-28	109
201	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society	100
200	Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. <b>2011</b> , 5, 449-55	38
199	Heart Failure as a Consequence of Hypertension. <b>2011</b> , 435-444	
198	Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. <b>2011</b> , 16, 1364-87	18
197	Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. <b>2011</b> , 29, 357-63	16
196	Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study. <b>2011</b> , 75, 806-14	2
195	The effects of captopril on cardiac regression, blood pressure and bradykinin components in diabetic Wistar Kyoto rats. <b>2011</b> , 24, 337-43	3
194	Distribution of a novel angiotensin I-converting enzyme inhibitory substance (2?-hydroxynicotianamine) in the flour, plant parts, and processed products of buckwheat. <b>2011</b> , 125, 607-613	12
193	ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <b>2011</b> , 123, 2434-506	255
192	Association of echocardiographic left ventricular structure with the ACE D/I polymorphism: a meta-analysis. <b>2011</b> , 12, 243-53	10
191	Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. <b>2011</b> , 25, 178-85	14
190	The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium. <b>2012</b> , 21, 146-52	6
189	Influence of dietary sodium modulation on electrocardiographic voltage criteria for left ventricular hypertrophy in normotensive individuals. <b>2012</b> , 60, 39-43	1

188	Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. <b>2012</b> , 30, 2039-46	17
187	Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. <b>2012</b> , 59, 901-9	396
186	Hypertension and exercise. <b>2012</b> , 31, 151-158	5
185	Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. <b>2012</b> , 1, 1-10	3
184	Rationale and design of a randomized study to determine the value of central Blood Pressure for GUIDing managEment of hypertension: the BP GUIDE study. <b>2012</b> , 163, 761-7	11
183	Aortic and left ventricular remodeling in patients with bicuspid aortic valve without significant valvular dysfunction: a prospective study. <b>2012</b> , 158, 347-52	40
182	Increased end diastolic wall stress precedes left ventricular hypertrophy in dilative heart failure--use of the volume-based wall stress index. <b>2012</b> , 157, 233-8	44
181	Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. <b>2012</b> , 13, 1515-26	18
180	Vasodilators across the heart failure spectrum not all patients, and not all vasodilators, are created equal. <b>2012</b> , 59, 452-4	1
179	Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. <b>2012</b> , 13, 1091-9	9
178	[Hypertension and exercise]. <b>2012</b> , 31, 151-8	20
177	Use of carvedilol in hypertension: an update. <i>Vascular Health and Risk Management</i> , <b>2012</b> , 8, 307-22	4.4 23
176	Regression of cardiac hypertrophy in cyp1a1ren-2 transgenic rats. <b>2012</b> , 36, 373-8	4
175	Impact of kinins in the treatment of cardiovascular diseases. <b>2012</b> , 135, 94-111	62
174	Early identification of asymptomatic subjects at increased risk of heart failure and cardiovascular events: progress and future directions. <b>2013</b> , 22, 171-8	7
173	Randomized trial of guiding hypertension management using central aortic blood pressure compared with best-practice care: principal findings of the BP GUIDE study. <b>2013</b> , 62, 1138-45	102
172	Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. <b>2013</b> , 8, 203-10	75
171	Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension. <b>2013</b> , 35, 563-9	7



170	Citation classics in systematic reviews and meta-analyses: who wrote the top 100 most cited articles?. <b>2013</b> , 8, e78517		51
169	A Prospective, Double-blind, Randomised Controlled Trial of the Angiotensin Converting Enzyme Inhibitor Ramipril In Asymptomatic Aortic Stenosis (RIAS trial): Trial Protocol. <b>2014</b> , 04,		1
168	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. <b>2014</b> , 32, 2038-44; discussion 2044		13
167	Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. <b>2014</b> , 63, 1916-23		81
166	Hypertension as a risk factor for heart failure. <b>2014</b> , 16, 447		35
165	Quantification of left ventricular functional parameter values using 3D spiral bSSFP and through-time non-Cartesian GRAPPA. <b>2014</b> , 16, 65		21
164	Cardiorespiratory fitness, exercise, and blood pressure. <b>2014</b> , 64, 1160-4		69
163	Renin-angiotensin system inhibitors and troponin elevation in spinal surgery. <b>2014</b> , 21, 1133-40		4
162	Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2015</b> , 65, 640-8	3.1	7
161	A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). <b>2015</b> , 16, 834-41		73
160	Obesity indices and haemodynamic response to exercise in obese diabetic hypertensive patients: Randomized controlled trial. <b>2015</b> , 9, 475-86		10
159	Molecular Targets in the Treatment of Cardiac Hypertrophy. <b>2015</b> , 343-371		1
158	Spinal NF- $\kappa$ B and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. <b>2015</b> , 10, e0115120		26
157	Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. <b>2015</b> , 16, 672-80		33
156	Systolic blood pressure values might further risk-stratify the adverse outcomes of LVH in older patients with chronic kidney disease. <b>2016</b> , 22, 21		2
155	The advantages of combination therapy on hypertension: development of immediate release perindopril-indapamide tablet and assessment of bioequivalence studies. <b>2016</b> , 21, 239-49		2
154	Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients. <b>2016</b> , 31, 1826-1833		6
153	Atenolol vs enalapril in young hypertensive patients after successful repair of aortic coarctation. <b>2016</b> , 30, 363-7		6

152	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. <b>2017</b> , 19, 12	14
151	Antihypertensive Therapies and Left Ventricular Hypertrophy. <b>2017</b> , 19, 79	25
150	Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension. <b>2017</b> , 6,	23
149	Coronary flow reserve in patients with resistant hypertension. <b>2017</b> , 106, 151-157	17
148	Hypertension and left ventricular hypertrophy. <b>2017</b> , 5, 310	29
147	Hypertensive heart disease in Africa. <b>2017</b> , 6,	0
146	Current Indications for Surgical Treatment of Primary Hyperparathyroidism in the Elderly. <b>2017</b> , 83, 296-302	2
145	ARTERIAL HYPERTENSION IN THE PRESENCE OF OVERWEIGHT AND OBESITY. THE CAPABILITIES OF AMLODIPINE AND LISINAPRIL COMBINATION. Part 2. Antihypertensive and Organoprotective Effects of Amlodipine/Lisinopril Fixed-Dose Combination in Patients with Arterial Hypertension in the Presence of Overweight and Obesity. <b>2017</b> , 13, 841-850	1
144	Hydrochlorothiazide and alternative diuretics versus renin-angiotensin system inhibitors for the regression of left ventricular hypertrophy: a head-to-head meta-analysis. <b>2018</b> , 36, 1247-1255	17
143	Left Ventricular Hypertrophy and Coronary Artery Calcifications: A Dangerous Duet?. <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 287-289	2,3 4
142	Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. <b>2018</b> , 8, e020255	14
141	Changes in left ventricular geometry during antihypertensive treatment. <b>2018</b> , 134, 193-199	20
140	The Renin-Angiotensin System and the Heart. <b>2018</b> , 43-55	1
139	Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. <b>2019</b> , 9, 10139	2
138	Hypertension and Heart Failure. <b>2019</b> ,	
137	Regression Under Treatment of Left Ventricular Hypertrophy and Other Structural Alterations. <b>2019</b> , 299-310	
136	Potential Protective Role of Blood Pressure-Lowering Drugs on the Balance between Hemostasis and Fibrinolysis in Hypertensive Patients at Rest and During Exercise. <b>2019</b> , 19, 133-171	4
135	Heart Failure as a Consequence of Hypertension. <b>2020</b> , 333-346.e6	

134	Level of Physical Activity, Left Ventricular Mass, Hypertension, and Prognosis. <b>2020</b> , 75, 693-701		2
133	Effect of renal denervation on catecholamines and the renin-angiotensin-aldosterone system. <b>2020</b> , 21, 1470320320943095		3
132	A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy. <b>2020</b> , 22, 85		3
131	Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. <b>2021</b> , 1		0
130	Prevalence of and risk factors for abnormal left ventricular geometrical patterns in hypertensive subjects administered irbesartan. <b>2021</b> , 35, e23688		0
129	Short-term repeatability of the peguero-lo presti electrocardiographic left ventricular hypertrophy criteria. <b>2021</b> , 26, e12829		2
128	Deep learning to estimate cardiac magnetic resonance-derived left ventricular mass.. <b>2021</b> , 2, 109-117		2
127	Correlation of Coronary Artery Disease and Left Ventricular Hypertrophy. <b>2021</b> , 13, e17550		0
126	Potential of valsartan+sacubitril therapy in hypertensive heart disease. <b>2021</b> , 26, 4568		0
125	Organ and Metabolic Complications: Cardiac. <b>1996</b> , 990-1002		1
124	Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. <b>1995</b> , 89-97		1
123	Renin-angiotensin system gene polymorphisms and left ventricular hypertrophy. The case against an association. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 117-22	3.6	7
122	Left ventricular hypertrophy and arterial hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 123-33	3.6	9
121	Physiological Versus Pathological Hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 145-158	3.6	4
120	Bradykinin and cardiac protection. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 159-72	3.6	6
119	Comparison of therapeutic studies on regression of left ventricular hypertrophy. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 191-8	3.6	9
118	Prognostic significance of left ventricular hypertrophy regression. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 199-205	3.6	9
117	Hypertensive heart disease, ventricular dysrhythmias, and sudden death. <i>Advances in Experimental Medicine and Biology</i> , <b>1997</b> , 432, 263-72	3.6	4

116	Angiotensin II in cell growth and matrix production. <i>Advances in Experimental Medicine and Biology</i> , <b>1995</b> , 377, 217-23	3.6	30
115	Hypertension and Prevention of Diastolic Heart Failure in the Aging Population. <b>2014</b> , 35-45		3
114	Kinins in the Heart. <b>1999</b> , 137-158		5
113	Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. <i>Basic Research in Cardiology</i> , <b>1993</b> , 88 Suppl 1, 1-14	11.8	35
112	Antihypertensiva. <i>Springer-Lehrbuch</i> , <b>1997</b> , 349-378	0.4	0
111	Does the combination of an ace inhibitor and a calcium antagonist enhance cardioprotection?. <b>1995</b> , 173-179		1
110	Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension. <b>2005</b> , 250-280		1
109	Quantitative Evaluation of Left Ventricular Structure, Wall Stress, and Systolic Function. <b>2007</b> , 187-211		2
108	Relationship between left ventricular mass and blood pressure in treated hypertension.		1
107	Angiotensin II receptor antagonists role in arterial hypertension.		1
106	Pulsatile hemodynamics in hypertension. <b>1999</b> , 14, 361-9		15
105	Cardiovascular hypertrophy: role of angiotensin II and bradykinin. <i>Journal of Cardiovascular Pharmacology</i> , <b>1996</b> , 27 Suppl 2, S36-40	3.1	32
104	Physical performance is preserved after regression of left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , <b>1997</b> , 30, 383-91	3.1	6
103	The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. <i>Journal of Cardiovascular Pharmacology</i> , <b>1997</b> , 30, 643-8	3.1	7
102	Gene expression of endothelin-1 and endothelial-type nitric oxide synthase in cardiovascular tissues of stroke-prone spontaneously hypertensive rats/lzm: effects of the angiotensin-converting enzyme inhibitor aracepril. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 31 Suppl 1, S395-8	3.1	5
101	Benefits of combination therapy in hypertensive patients with associated coronary artery disease: a subgroup with specific demands. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 31 Suppl 2, S27-33	3.1	3
100	Hypertension and the development of heart failure. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32 Suppl 1, S9-15	3.1	10
99	Effect of quinapril and triamterene/hydrochlorothiazide on cardiac and vascular end-organ damage in isolated systolic hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 31, 187-94	3.1	13

98	Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32, 760-8	3.1	7
97	Reduced periinfarction mortality as a result of long-term therapy with captopril but not hydralazine or propranolol in spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , <b>1998</b> , 32, 884-95	3.1	5
96	Angiotensin II Antagonism and the Heart: Valsartan in Left Ventricular Hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 33, S33-S36	3.1	5
95	The effects of mibefradil and enalapril on 24-hour blood pressure control and left ventricular mass in patients with mild to moderate hypertension: double-blind, randomized trial. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 33, 647-51	3.1	3
94	Antihypertensive effect of trandolapril and verapamil in rats with induced hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 33, 748-55	3.1	3
93	Clinical experience with spirapril in human hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34 Suppl 1, S25-30	3.1	2
92	Time course of the effects of temocapril on cardiovascular structure and function in patients with essential hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 561-6	3.1	8
91	Insulin resistance in chronic heart failure. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, S9-14	3.1	66
90	Effects of long-term treatment with nonselective endothelin receptor antagonist, TAK-044, on remodeling of cardiovascular system with sustained volume overload. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 35, 777-85	3.1	8
89	Effects of indapamide in rats with pressure overload left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 36, 481-6	3.1	11
88	Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). <b>1995</b> , 91, 698-706		200
87	Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. <b>1996</b> , 93, 1148-54		68
86	Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. <b>1996</b> , 94, 1304-9		92
85	ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. <b>1997</b> , 95, 1461-71		431
84	Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. <b>1997</b> , 95, 2007-14		184
83	Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. <b>1997</b> , 96, 864-73		51
82	Microalbuminuria and erythrocyte sodium-hydrogen exchange in essential hypertension. <b>1995</b> , 25, 981-5		6
81	Prevalence and determinants of cardiac and vascular hypertrophy in hypertension. <b>1995</b> , 26, 369-73		61

80	Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. <b>1996</b> , 28, 269-75		117
79	Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries. <b>1996</b> , 28, 450-6		11
78	Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. <b>1995</b> , 96, 1490-8		75
77	Cardiac ankyrin repeat protein attenuates cardiac hypertrophy by inhibition of ERK1/2 and TGF- $\beta$ signaling pathways. <b>2012</b> , 7, e50436		30
76	The influence of Angiotensin converting enzyme and angiotensinogen gene polymorphisms on hypertrophic cardiomyopathy. <b>2013</b> , 8, e77030		12
75	HYPERPARATHYROIDISM AND CARDIOVASCULAR SYSTEM PATHOLOGY. <b>2006</b> , 9, 33-41		1
74	Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect. <b>2020</b> , 11, 376-385		1
73	Angiotensin II promotes integrin-mediated collagen gel contraction by adult rat cardiac fibroblasts. <i>International Heart Journal</i> , <b>1999</b> , 40, 461-9		19
72	Arterial hypertension in adults. Clinical guidelines 2020. <b>2020</b> , 25, 3786		155
71	Actual aspects of pathogenesis and treatment of asymmetric left ventricular hypertrophy in essential hypertension. <i>Arterial Hypertension (Russian Federation)</i> , <b>2008</b> , 14, 360-368	0.7	1
70	Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. <i>Vascular Health and Risk Management</i> , <b>2008</b> , 4, 67-73	4.4	18
69	Cardiovascular Drug Therapy in the Elderly. <i>Fundamental and Clinical Cardiology</i> , <b>2008</b> , 99-136		4
68	Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , <b>2021</b> , 20, 2845	0.9	
67	Literaturverzeichnis. <b>2000</b> , 63-75		
66	Effects of antihypertensive therapy on blood pressure and left ventricular hypertrophy in patients with severe hypertension. <i>International Heart Journal</i> , <b>2000</b> , 41, 339-48		
65	Diastolic Dysfunction and Diastolic Heart Failure. <i>Progress in Experimental Cardiology</i> , <b>2000</b> , 441-452		
64	The Effects of $\beta$ -Blockade on the Cardiovascular System [Not all $\beta$ -Blockers are Created Equal. <b>2001</b> , 29-38		
63	Evaluative and epidemiological approaches of ACE therapy. <b>2001</b> , 47-70		

- 62 Antihypertensive Agents: Mechanisms of Drug Action. **2001**, 144-161
- 61 Risk Factors for Atherosclerosis in the Elderly. **2001**, 448-459
- 60 The Therapeutic Trials. **2001**, 162-184
- 59 Antihypertensiva. *Springer-Lehrbuch*, **2002**, 361-391 0.4
- 58 Antihypertensive Agents: Mechanisms of Drug Action. **2003**, 155-174
- 57 Dietary Prevention of CHD. **2003**,
- 56 Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists. *Handbook of Experimental Pharmacology*, **2004**, 485-516 3.2
- 55 From early clinical studies to randomized controlled clinical trials. **2004**, 199-236
- 54 Coronary Atherosclerotic Sequelae of Hypertension. **2005**, 237-249
- 53 Antagonisty kal'tsiya v lechenii arterial'noy gipertonii (issledovanie ETNA). *Systemic Hypertension*, **2005**, 2, 25-28 1.6
- 52 Antihypertensive and cardiovascular effects of combined blockade of renin-angiotensin system with ACE inhibitor and angiotensin II type 1 receptor blocker in hypertensive patients: A 24-week randomized controlled double-dummy trial. *Heart International*, **2006**, 2, 39 0.3
- 51 Primenenie inhibitorov angiotenzinprevrashchayushchego fermenta v lechenii arterial'noy gipertonii. *Systemic Hypertension*, **2006**, 3, 46-49 1.6
- 50 Hypertension: Impact of Echocardiographic Data on the Mechanism of Hypertension, Treatment, Options, Prognosis, and Assessment of Therapy. **2007**, 816-847
- 49 ACE Inhibition in Heart Failure and Ischaemic Heart Disease. **2007**, 21-54
- 48 Determinants of evolution of ECG signs of left ventricular hypertrophy during long-term antihypertensive treatment in patients with high risk arterial hypertension. *Arterial Hypertension (Russian Federation)*, **2007**, 13, 39-43 0.7
- 47 Left ventricular hypertrophy and angiotensin II receptor blockers. From clinical studies to clinical guidelines. *Arterial Hypertension (Russian Federation)*, **2008**, 14, 281-284 0.7
- 46 The place of calcium antagonists in the treatment of hypertension in patients with coronary artery disease. *Arterial Hypertension (Russian Federation)*, **2008**, 14, 275-280 0.7
- 45 The Renin-Angiotensin System and the Heart. **2009**, 181-188 0

- 44 Combination antihypertensive therapy - newer indications. *Arterial Hypertension (Russian Federation)*, **2009**, 15, 46-49 0.7 1
- 43 Risk Factors for Atherosclerosis in the Elderly. **2011**, 635-648
- 42 Diuretikatherapie. **1993**, 81-97
- 41 Lokale Expression und pathophysiologische Rolle von Renin-Angiotensin im Gefäßsystem und im Herzen. **1993**, 1-15
- 40 Pathophysiology of hypertension in the elderly. **1993**, 147-152
- 39 Arterial system, left ventricular structure and function. *Developments in Cardiovascular Medicine*, **1993**, 155-179
- 38 Treatment of hypertension and concomitant disease in the elderly. *Developments in Cardiovascular Medicine*, **1994**, 51-69
- 37 Ventricular tachyarrhythmias, myocardial ischemia and sudden cardiac death in patients with hypertensive heart disease. **1994**, 191-204
- 36 ACE-Hemmer. **1996**, 1365-1383
- 35 Calciumantagonisten bei koronarer Herzkrankheit. **1996**, 121-160
- 34 Calciumantagonisten bei essentieller Hypertonie. **1996**, 175-192
- 33 Klinischer Einsatz der ACE-Hemmer. *Aktuelle Therapieprinzipien in Kardiologie Und Angiologie*, **1996**, 123-165
- 32 Comparison of meta-analyses of therapeutic studies on regression of left ventricular hypertrophy. *Advances in Experimental Medicine and Biology*, **1997**, 432, 189-90 3.6
- 31 Noninvasive Evaluation of Aortic Elastic Properties. *Developments in Cardiovascular Medicine*, **1997**, 99-122
- 30 Moderatormanual Hypertonie. **1998**, 85-128
- 29 Cardiovascular Complications in Uremia and Dialysis. **1998**, 817-839
- 28 Hypertension and the Development of Heart Failure. *Journal of Cardiovascular Pharmacology*, **1998**, 32, S9-S15 3.1
- 27 ??????????(????????)(????????). *Journal of JCS Cardiologists*, **1998**, 6, 11-17 0.1



26	Left Ventricular Hypertrophy: Reversal by Antihypertensive Therapy. <i>Developments in Cardiovascular Medicine</i> , <b>1999</b> , 131-138		
25	Negative U-wave as a predictor of antihypertensive treatment effect on regression of echocardiographic hypertrophy in hypertensive patients. <i>International Heart Journal</i> , <b>1999</b> , 40, 31-44		
24	Antihypertensiva. <i>Springer-Lehrbuch</i> , <b>1999</b> , 349-378	0.4	
23	Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. <i>International Heart Journal</i> , <b>1999</b> , 40, 55-63		
22	Microvascular Angina and Hypertensive Left Ventricular Hypertrophy. <i>Developments in Cardiovascular Medicine</i> , <b>1999</b> , 269-279		
21	Clinical Experience with Spirapril in Human Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, S25-S30	3.1	5
20	Factors Contributing to Development and Reversal of LVH: A Pilot Study. <i>Journal of Clinical and Diagnostic Research JCDR</i> , <b>2016</b> , 10, OC17-20	0	1
19	The Progression of Hypertensive Heart Disease to Left Ventricular Hypertrophy and Heart Failure. <b>2016</b> , 59-74		
18	Clinical efficacy and cardioprotective capabilities of olmesartan and lercanidipine in the form of monotherapy and with their combined use in patients with arterial hypertension 1-2 degree. <i>Cardiosomatics</i> , <b>2017</b> , 8, 89-97	0.4	
17	The Impact of Cardiorespiratory Fitness on Cardiometabolic Risk Factors and Mortality. <i>Bioengineered</i> , <b>2017</b> , 6, 71-77	5.7	
16	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , <b>2018</b> , 320-342	0.2	
15	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. <b>2019</b> , 218-240		
14	Chinese Herbal Medicine in the Management of Atherosclerosis-Related Chronic Conditions in an Aging Population. <b>2019</b> , 593-615		
13	Deep Learning to Estimate Cardiac Magnetic Resonance-Derived Left Ventricular Mass.		1
12	Congestive heart failure arising from diastolic dysfunction in the presence of normal left-ventricular systolic function. <i>Texas Heart Institute Journal</i> , <b>1999</b> , 26, 34-41	0.8	5
11	Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension. <i>Cmaj</i> , <b>1993</b> , 149, 575-84	3.5	17
10	Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 371-80	4.4	3
9	Angiotensin-converting enzyme and angiotensinogen gene polymorphism in hypertrophic cardiomyopathy. <i>Experimental and Clinical Cardiology</i> , <b>2003</b> , 8, 155-9		9

8	Natural occurrence of aflatoxin residues in fresh and sun-dried meat in Nigeria. <i>Pan African Medical Journal</i> , <b>2010</b> , 7, 14	1.2	2
7	sST2 Predicts Short Term Therapy Success in Patients with Therapy Resistant Hypertension after Renal Sympathetic Denervation. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 11130	2.6	1
6	Remodelling of the heart is not a proven clinical concept. <i>Basic Research in Cardiology</i> , <b>1997</b> , 92 Suppl 2, 62-4	11.8	
5	Quantitative Evaluation of Left Ventricular Structure, Wall Stress, and Systolic Function. <b>2017</b> , 107-127		1
4	The Diabetic Cardiorenal Nexus. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23, 7351	6.3	1
3	Antihypertensives in Children and Adolescents.		0
2	Hipertansif Hastalarda Angiotensin Tip 1 ResptBlokEleri ile Tedavi Etkisinin Egzersiz Doku Doppler Ekokardiyografik Parametrelerle DeBrlendirilmesi.		0
1	The fundus of the eye as a target organ in hypertension: a literature review. <b>2023</b> , 13, 213-222		0